PMID- 32457058
OWN - NLM
STAT- MEDLINE
DCOM- 20210219
LR  - 20210802
IS  - 1935-5548 (Electronic)
IS  - 0149-5992 (Print)
IS  - 0149-5992 (Linking)
VI  - 43
IP  - 8
DP  - 2020 Aug
TI  - C-Peptide Levels in Subjects Followed Longitudinally Before and After Type 1 
      Diabetes Diagnosis in TrialNet.
PG  - 1836-1842
LID - 10.2337/dc19-2288 [doi]
AB  - OBJECTIVE: Insulin secretion declines rapidly after diagnosis of type 1 diabetes, 
      followed by a slower rate of change. Previous studies have demonstrated that the 
      C-peptide decline begins before the clinical diagnosis. Changes in insulin 
      secretion in the same individuals studied from preclinical stages through and 
      after clinical diagnosis have not been previously reported. RESEARCH DESIGN AND 
      METHODS: Antibody-positive relatives undergo sequential oral glucose tolerance 
      testing (OGTT) as part of TrialNet's Pathway to Prevention study and continue 
      both OGTT and mixed-meal tolerance testing (MMTT) as part of the Long-term 
      Investigational Follow-up in TrialNet study if they develop type 1 diabetes. We 
      analyzed glucose and C-peptide data obtained from 80 TrialNet subjects who had 
      OGTT before and after clinical diagnosis. Separately, we compared C-peptide 
      response to OGTT and MMTT in 127 participants after diagnosis. RESULTS: C-peptide 
      did not change significantly until 6 months before the clinical diagnosis of type 
      1 diabetes and continued to decline postdiagnosis, and the rates of decline for 
      the first 6 months postdiagnosis were similar to the 6 months prediagnosis. There 
      were no significant differences in MMTT and OGTT C-peptide responses in paired 
      tests postdiagnosis. CONCLUSIONS: This is the first analysis of C-peptide levels 
      in longitudinally monitored patients with type 1 diabetes studied from before 
      diagnosis and continuing to the postdiagnosis period. These data highlight the 
      discordant timing between accelerated beta-cell dysfunction and the current glucose 
      thresholds for clinical diagnosis. To preserve beta-cell function, disease-modifying 
      therapy should start at or before the acute decline in C-peptide.
CI  - (c) 2020 by the American Diabetes Association.
FAU - Bogun, Magdalena M
AU  - Bogun MM
AUID- ORCID: 0000-0002-3162-9157
AD  - Columbia University, New York, NY mmb2263@cumc.columbia.edu.
FAU - Bundy, Brian N
AU  - Bundy BN
AD  - University of South Florida, Tampa, FL.
FAU - Goland, Robin S
AU  - Goland RS
AD  - Columbia University, New York, NY.
FAU - Greenbaum, Carla J
AU  - Greenbaum CJ
AUID- ORCID: 0000-0003-4451-9800
AD  - Benaroya Research Institute, Seattle, WA.
LA  - eng
GR  - U01 DK085476/DK/NIDDK NIH HHS/United States
GR  - U01 DK061010/DK/NIDDK NIH HHS/United States
GR  - U01 DK085453/DK/NIDDK NIH HHS/United States
GR  - U01 DK103282/DK/NIDDK NIH HHS/United States
GR  - UC4 DK106993/DK/NIDDK NIH HHS/United States
GR  - U01 DK061042/DK/NIDDK NIH HHS/United States
GR  - U01 DK085509/DK/NIDDK NIH HHS/United States
GR  - UC4 DK117009/DK/NIDDK NIH HHS/United States
GR  - U01 DK085466/DK/NIDDK NIH HHS/United States
GR  - U01 DK103153/DK/NIDDK NIH HHS/United States
GR  - U01 DK061058/DK/NIDDK NIH HHS/United States
GR  - U01 DK106984/DK/NIDDK NIH HHS/United States
GR  - U01 DK085499/DK/NIDDK NIH HHS/United States
GR  - U01 DK107013/DK/NIDDK NIH HHS/United States
GR  - U01 DK103266/DK/NIDDK NIH HHS/United States
GR  - U01 DK107014/DK/NIDDK NIH HHS/United States
GR  - U01 DK106994/DK/NIDDK NIH HHS/United States
GR  - U01 DK061034/DK/NIDDK NIH HHS/United States
GR  - U01 DK085461/DK/NIDDK NIH HHS/United States
GR  - UC4 DK097835/DK/NIDDK NIH HHS/United States
GR  - U01 DK103180/DK/NIDDK NIH HHS/United States
GR  - U01 DK085465/DK/NIDDK NIH HHS/United States
GR  - U01 DK085504/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20200526
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
RN  - 0 (Blood Glucose)
RN  - 0 (C-Peptide)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Blood Glucose/metabolism
MH  - C-Peptide/analysis/*blood
MH  - Child
MH  - Child, Preschool
MH  - Cohort Studies
MH  - Diabetes Mellitus, Type 1/*blood/complications/*diagnosis/pathology
MH  - Diagnostic Techniques, Endocrine
MH  - Disease Progression
MH  - Female
MH  - Follow-Up Studies
MH  - Glucose Tolerance Test
MH  - Humans
MH  - Insulin Secretion/physiology
MH  - Longitudinal Studies
MH  - Male
MH  - Meals
MH  - Middle Aged
MH  - Monitoring, Physiologic
MH  - Young Adult
PMC - PMC7372058
EDAT- 2020/05/28 06:00
MHDA- 2021/02/20 06:00
PMCR- 2021/08/01
CRDT- 2020/05/28 06:00
PHST- 2019/11/14 00:00 [received]
PHST- 2020/04/19 00:00 [accepted]
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
PHST- 2020/05/28 06:00 [entrez]
PHST- 2021/08/01 00:00 [pmc-release]
AID - dc19-2288 [pii]
AID - 192288 [pii]
AID - 10.2337/dc19-2288 [doi]
PST - ppublish
SO  - Diabetes Care. 2020 Aug;43(8):1836-1842. doi: 10.2337/dc19-2288. Epub 2020 May 
      26.